Effects of CYP3A4*22 and CYP3A5 on clinical outcome in patients treated with ticagrelor for ST-segment elevation myocardial infarction: POPular Genetics sub-study

• Egile Nagusiak: Jaouad Azzahhafi (Egilea), Thomas O. Bergmeijer (Egilea), Wout W. A. van den Broek (Egilea), Dean R. P. P. Chan Pin Yin (Egilea), Senna Rayhi (Egilea), Joyce Peper (Egilea), Willem L. Bor (Egilea), Daniel M. F. Claassens (Egilea), Ron H. N. van Schaik (Egilea), Jurriën M. ten Berg (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Aims: To determine the clinical efficacy, adverse events and side-effect dyspnea of CYP3A4*22 and CYP3A5 expressor status in ticagrelor treated patients.Methods and results: Ticagrelor treated patients from the POPular Genetics randomized controlled trial were genotyped for CYP3A4*22 and CYP3A5*3 al...